S

Sana Biotechnology Inc
NASDAQ:SANA

Watchlist Manager
Sana Biotechnology Inc
NASDAQ:SANA
Watchlist
Price: 2.61 USD 11.06% Market Closed
Market Cap: 580.6m USD
Have any thoughts about
Sana Biotechnology Inc?
Write Note

Sana Biotechnology Inc
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sana Biotechnology Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
S
Sana Biotechnology Inc
NASDAQ:SANA
Total Other Income
-$52k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Other Income
-$4.6B
CAGR 3-Years
12%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Total Other Income
$302m
CAGR 3-Years
76%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Total Other Income
$578m
CAGR 3-Years
81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Other Income
-$68m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Other Income
$6m
CAGR 3-Years
-49%
CAGR 5-Years
-35%
CAGR 10-Years
8%
No Stocks Found

Sana Biotechnology Inc
Glance View

Market Cap
582.3m USD
Industry
Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 383 full-time employees. The company went IPO on 2021-02-04. The firm is focused on creating and delivering engineered cells as medicines for patients. The firm develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

SANA Intrinsic Value
0.92 USD
Overvaluation 65%
Intrinsic Value
Price
S

See Also

What is Sana Biotechnology Inc's Total Other Income?
Total Other Income
-52k USD

Based on the financial report for Dec 31, 2023, Sana Biotechnology Inc's Total Other Income amounts to -52k USD.

What is Sana Biotechnology Inc's Total Other Income growth rate?
Total Other Income CAGR 1Y
92%

Over the last year, the Total Other Income growth was 92%.

Back to Top